Cord Blood News Volume 8.03 | Jan 28 2016

Mesenchymal Stem Cells and Mononuclear Cells From Cord Blood: Cotransplanation Provides a Better Effect in Treating Myocardial Infarction
Investigators evaluated the effect of cotransplanting mononuclear cells from cord blood and mesenchymal stem cells as treatment for myocardial infarction. [Stem Cells Transl Med] Abstract

Reduced Intensity Conditioning Regimen with Fludarabine, Cyclophosphamide, Low Dose TBI and Alemtuzumab Leading to Successful Unrelated Umbilical Cord Stem Cell Engraftment and Survival in Two Children with Dyskeratosis Congenita
Researchers report the hematopoietic stem cell transplantation course of two patients with successful restoration of hematopoiesis following reduced intensity conditioning and unrelated cord blood transplant. [Bone Marrow Transplant] Abstract

Immunomodulatory Effects of Amniotic Membrane Matrix Incorporated into Collagen Scaffolds
Researchers showed that scaffolds containing amniotic membrane matrix have significantly increased mechanical properties and that tendon cells within these scaffolds have increased metabolic activity even when the media is supplemented with the pro-inflammatory cytokine interleukin-1 beta. [J Biomed Mater Res A] Abstract

Maternal Obesity Associated with Increase in Natural Killer T Cells and CD8⁺ Regulatory T Cells in Cord Blood Units
Scientists determined if obstetric, maternal, and fetal factors modify the number of lymphocyte subsets in umbilical cord blood units. [Transfusion] Abstract

A Comparison of Tacrolimus and Cyclosporine Combined with Methotrexate for Graft-Versus-Host Disease Prophylaxis, Stratified by Stem Cell Source: A Retrospective Nationwide Survey
Investigators compared the efficacy of cyclosporine and tacrolimus with methotrexate for acute graft-versus-host disease prevention and transplant-related outcomes. [Int J Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Stemedica Cell Technologies Announces Completion of Enrollment in Phase I/IIa Clinical Trial for Ischemic Stroke
Stemedica Cell Technologies, Inc. announced completion of enrollment into “A Phase I/IIa, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke.” [Stemedica Cell Technologies, Inc.] Press Release

AbbVie’s Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
AbbVie announced that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. [AbbVie Inc.] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells. Watch now.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Research Fellow/Research Officer – Zeb2 Transcription Factor in Hematopoietic Stem Cell Differentiation (Monash University)

PhD Position – Stem Cells and Transplantation (University of Geneva)

Postdoctoral Fellow – Stem Cell Biology (Krembil Research Institute)

Research Specialist – Stem Cells from the Hematopoietic System (Howard Hughes Medical Institute)

Doctoral Fellow – Stem Cell Research (Krembil Research Institute)

Postdoctoral position – Regenerative Medicine (University of Copenhagen)

Stem Cell Scientist and Postdoctoral Positions (National Center for Advancing Translational Science)

Postdoctoral Position – Cell and Molecular Biology of Leukemia (Virginia Commonwealth University)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.